From the first U.S. Shockwave C2+ case to the unveiling of the 2023 TopShock finalists, this past quarter had a lively pulse all its own. In other news, we’re very excited to share the impressive results from the 2-year DISRUPT CAD III study of IVL for Treatment of Severely Calcified Coronary Arteries.
For our international customers, there was an excellent poster session presented during ESC Congress that featured three presentations on our Coronary Sinus Reducer*. We also launched a series of real-world application videos from VAM 2023 that highlight Shockwave L6 and the benefits of using it to tackle calcium in large vessels. Dive head first into the latest PulsePoint Newsletter to learn more about the big waves made in Q3!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD,
Reducer
Over the past three months, Shockwave continued to ride a big wave of momentum with new product launches, inclusions in new journal articles, a pulse-racing presence at EuroPCR and more. The launch of Shockwave L6 Peripheral IVL Catheter in the U.S. came with physician-led case reviews, Q&As and more valuable content that demonstrate the big impact it can make in large peripheral vessels. We also turned up the heat at EuroPCR in Paris, where we showcased live cases, hosted an engaging symposium and participated in PCR TV interviews - all while focusing heavily on the European launch of our Shockwave C2+ Coronary IVL Catheter, which includes 50% more pulses than the original Shockwave C2. Dive right in and catch the wave of excitement in the latest issue of the PulsePoint newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
2023 was off to a shockingly great start! We were thrilled to acquire Neovasc, a company with a first-of-its-kind technology to address refractory angina, and are looking forward to driving value for physicians and improving the lives of an underserved patient population. The excitement for our new peripheral product, Shockwave L6, was electrifying and has continued to make waves across the U.S. Shockwave IVL and Coronary IVL became listed by SCAI as a potential therapy option across all U.S. cath labs regardless of surgical backup status. As always, we were further confirming the efficacy and safety of Shockwave IVL across different calcium morphologies through new publications. We highlight these topics and more in our latest PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
Dr. Jaikirshan J. Khatri, MD, FACC, FSCAI Director of Complex Coronary Intervention Heart, Vascular & Thoracic Institute, at Cleveland Clinic; Cleveland, Ohio shares his calcium modification approach with Coronary IVL including his best practices for pulse management as well as how calcium is affected by the fractures caused by coronary IVL.
Read More
Topics:
Coronary IVL,
Shockwave C2,
Calcium Corner
Dr. Suzanne J. Baron of Lahey Hospital and Medical Center, Burlington, Massachusetts talks about gender disparities of PCI outcomes in calcified lesions, citing the recent SCAI Expert Consensus Statement, which brings to light the under-representation of women in cardiovascular clinical trials. Dr. Baron also talks about the impact of IVL to improve outcomes in women with calcified disease based on the recently published sex specific analysis of Disrupt CAD Pooled data at SCAI 2022.
For more information on Coronary IVL CAD Pooled Gender Analysis data, please visit ItsTimeForAnIntervention.com
Read More
Topics:
Coronary IVL,
Shockwave C2,
Calcium Corner
Dr. Stephan Heo of the New England Heart and Vascular Institute, Catholic Medical Center, Manchester, New Hampshire shares his decision-making process in approaching calcified lesions in complex PCI as well as strategies to deliver IVL with different GEC techniques when facing challenging vessel anatomy and calcium morphology.
Read More
Topics:
Coronary IVL,
Shockwave C2,
Calcium Corner
Dr. Kevin Croce, Director of Chronic Total Occlusion (CTO)/Complex PCI Program, Interventional Cardiologist, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Boston Massachusetts talks about the importance of image guided plaque modification in optimizing PCI, discusses the role of IVL in calcium modification and share his insights on Coronary IVL in different calcium morphologies.
Read More
Topics:
Coronary IVL,
Shockwave C2,
Calcium Corner
Dr. B. Clay Sizemore, Interventional Cardiologist at Cardiovascular Consultants of South Georgia, Thomasville, GA speaks about his experience with coronary IVL in a no surgical backup hospital, discussing his patient selection criteria, importance of same day discharge and how IVL fits well into this strategy, thereby allowing the treatment of previously undilatable calcified lesions and minimizing the risk of patient transfer and procedure staging.
Read More
Topics:
Coronary IVL,
Shockwave C2,
Calcium Corner